Immune responses regulating the response to vascular injury

Current Opinion in Lipidology

Volumn 21, Issue 5, 2010, Pages 416-421

  Dimayuga, Paul C ^a   Chyu, Kuang Yuh ^a   Cercek, Bojan ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

immune response; neointima; vascular injury

Indexed keywords

ANTIBODY; ANTICOAGULANT AGENT; C REACTIVE PROTEIN; CD40 ANTIGEN; CD40 LIGAND; IMMUNOGLOBULIN M ANTIBODY; RAPAMYCIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ADAPTIVE IMMUNITY; ARTERY INJURY; ATHEROSCLEROTIC PLAQUE; B LYMPHOCYTE; BLOOD VESSEL INJURY; DENDRITIC CELL; DRUG ELUTING STENT; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TISSUE INJURY; VASCULAR DISEASE;

ADAPTIVE IMMUNITY; ANIMALS; HUMANS; IMMUNITY, INNATE; IMMUNOSUPPRESSIVE AGENTS; VASCULAR SYSTEM INJURIES;

EID: 77957591828     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32833cacbe     Document Type: Review

References (64)

1. Grech ED. ABC of interventional cardiology: percutaneous coronary intervention I - history and development. BMJ 2003; 326:1080-1082.
2. Bjorkerud S, Bondjers G. Arterial repair and atherosclerosis after mechanical injury. I. Permeability and light microscopic characteristics of endothelium in nonatherosclerotic and atherosclerotic lesions. Atherosclerosis 1971; 13:355-363.
3. Ross R, Glomset J, Harker L. Response to injury and atherogenesis. Am J Pathol 1977; 86:675-684.
4. Hansson GK, Bondjers G, Nilsson LA. Plasma protein accumulation in injured endothelial cells. Immunofluorescent localization of IgG and fibrinogen in the rabbit aortic endothelium. Exp Mol Pathol 1979; 30:12-26.
5. Jonasson L, Holm J, Hansson GK. Smooth muscle cells express Ia antigens during arterial response to injury. Lab Invest 1988; 58:310-315.
6. Hansson GK, Holm J, Holm S, et al. T lymphocytes inhibit the vascular response to injury. Proc Natl Acad Sci U S A 1991; 88:10530-10534.
7. Remskar M, Li H, Chyu KY, et al. Absence of CD40 signaling is associated with an increase in intimal thickening after arterial injury. Circ Res 2001; 88:390-394.
8. Dimayuga P, Cercek B, Oguchi S, et al. Inhibitory effect on arterial injuryinduced neointimal formation by adoptive B-cell transfer in Rag-1 knockout mice. Arterioscler Thromb Vasc Biol 2002; 22:644-649.
9. Dimayuga PC, Li H, Chyu KY, et al. T cell modulation of intimal thickening after vascular injury: the bimodal role of IFN-gamma in immune deficiency. Arterioscler Thromb Vasc Biol 2005; 25:2528-2534.
10. Zhu B, Reardon CA, Getz GS, Hui DY. Both apolipoprotein E and immune deficiency exacerbate neointimal hyperplasia after vascular injury in mice. Arterioscler Thromb Vasc Biol 2002; 22:450-455.
11. Shi Y, Zheng W, Rock KL. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc Natl Acad Sci U S A 2000; 97:14590-14595.
12. Wallin RP, Lundqvist A, More SH, et al. Heat-shock proteins as activators of the innate immune system. Trends Immunol 2002; 23:130-135.
13. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007; 81:1-5.
14. Kim KD, Zhao J, Auh S, et al. Adaptive immune cells temper initial innate responses. Nat Med 2007; 13:1248-1252.
15. Mombaerts P, Iacomini J, Johnson RS, et al. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992; 68:869-877.
16. Dimayuga PC, Cesena FH, Chyu KY, et al. Natural antibodies and complement modulate intimal thickening after arterial injury. Am J Physiol Regul Integr Comp Physiol 2009; 297:R1593-R1600.
17. Zhao J, Yang X, Auh SL, et al. Do adaptive immune cells suppress or activate innate immunity? Trends Immunol 2009; 30:8-12.
18. Harris AK, Shen J, Radford J, et al. GM-CSF deficiency delays neointima formation in a normolipidemic mouse model of endoluminal endothelial damage. Immunol Cell Biol 2009; 87:122-130.
19. Vink A, Schoneveld AH, van der Meer JJ, et al. In vivo evidence for a role of tolllike receptor 4 in the development of intimal lesions. Circulation 2002; 106:1985-1990.
20. Schoneveld AH, Oude Nijhuis MM, van Middelaar B, et al. Toll-like receptor 2 stimulation induces intimal hyperplasia and atherosclerotic lesion development. Cardiovasc Res 2005; 66:162-169.
21. Tang PC, Qin L, Zielonka J, et al. MyD88-dependent, superoxide-initiated inflammation is necessary for flow-mediated inward remodeling of conduit arteries. J Exp Med 2008; 205:3159-3171.
22. Shagdarsuren E, Bidzhekov K, Djalali-Talab Y, et al. C1-esterase inhibitor protects against neointima formation after arterial injury in atherosclerosisprone mice. Circulation 2008; 117:70-78.
23. Manderson AP, Pickering MC, Botto M, et al. Continual low-level activation of the classical complement pathway. J Exp Med 2001; 194:747-756.
24. Danenberg HD, Grad E, Swaminathan RV, et al. Neointimal formation is reduced after arterial injury in human crp transgenic mice. Atherosclerosis 2008; 201:85-91.
25. Xing D, Hage FG, Chen YF, et al. Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (Fc gamma RI)- dependent. Am J Pathol 2008; 172:22-30.
26. Kumar A, Lindner V. Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol 1997; 17:2238-2244.
27. Singh R, Pan S, Mueske CS, et al. Tissue factor pathway inhibitor deficiency enhances neointimal proliferation and formation in a murine model of vascular remodelling. Thromb Haemost 2003; 89:747-751.
28. Fleming SD, Tsokos GC. Complement, natural antibodies, autoantibodies and tissue injury. Autoimmun Rev 2006; 5:89-92.
29. Faria-Neto JR, Chyu KY, Li X, et al. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 2006; 189:83-90.
30. Zernecke A, Liehn EA, Gao JL, et al. Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10. Blood 2006; 107:4240-4243.
31. Kovacic JC, Gupta R, Lee AC, et al. Stat3-dependent acute Rantes production in vascular smooth muscle cells modulates inflammation following arterial injury in mice. J Clin Invest 2010; 120:303-314.
32. Weber C, Weber KS, Klier C, et al. Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and T(H)1-like/ CD45RO() T cells. Blood 2001; 97:1144-1146.
33. Camargo JF, Quinones MP, Mummidi S, et al. CCR5 expression levels influence NFAT translocation, IL-2 production, and subsequent signaling events during T lymphocyte activation. J Immunol 2009; 182:171-182.
34. Strom A, Wigren M, Hultgardh-Nilsson A, et al. Involvement of the CD1dnatural killer T cell pathway in neointima formation after vascular injury. Circ Res 2007; 101:e83-e89.
35. Van KL. NKT cells: T lymphocytes with innate effector functions. Curr Opin Immunol 2007; 19:354-364.
36. Kurobe H, Urata M, Ueno M, et al. Role of hypoxia-inducible factor 1alpha in T cells as a negative regulator in development of vascular remodeling. Arterioscler Thromb Vasc Biol 2010; 30:210-217.
37. Lukashev D, Caldwell C, Ohta A, et al. Differential regulation of two alternatively spliced isoforms of hypoxia-inducible factor-1 alpha in activated T lymphocytes. J Biol Chem 2001; 276:48754-48763.
38. Lukashev D, Klebanov B, Kojima H, et al. Cutting edge: hypoxia-inducible factor 1alpha and its activation-inducible short isoform I.1 negatively regulate functions of CD4 and CD8 T lymphocytes. J Immunol 2006; 177:4962-4965.
39. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A 1993; 90:4304-4308.
40. Richard DE, Berra E, Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem 2000; 275:26765-26771.
41. Karshovska E, Zernecke A, Sevilmis G, et al. Expression of HIF-1alpha in injured arteries controls SDF-1alpha mediated neointima formation in apolipoprotein E deficient mice. Arterioscler Thromb Vasc Biol 2007; 27:2540-2547.
42. Bobryshev YV, Lord RS. Ultrastructural recognition of cells with dendritic cell morphology in human aortic intima. Contacting interactions of vascular dendritic cells in athero-resistant and athero-prone areas of the normal aorta. Arch Histol Cytol 1995; 58:307-322.
43. Bauriedel G, Jabs A, Skowasch D, et al. Dendritic cells in neointima formation after rat carotid balloon injury: coordinated expression withanti-apoptotic Bcl-2 and HSP47 in arterial repair. J Am Coll Cardiol 2003; 42:930-938.
44. Han JW, Shimada K, Ma-Krupa W, et al. Vessel wall-embedded dendritic cells induce T-cell autoreactivity and initiate vascular inflammation. Circ Res 2008; 102:546-553.
45. Kosuge H, Suzuki J, Haraguchi G, et al. Critical role of inducible costimulator signaling in the development of arteriosclerosis. Arterioscler Thromb Vasc Biol 2006; 26:2660-2665.
46. Karube A, Suzuki J, Haraguchi G, et al. Suppression of neointimal hyperplasia after vascular injury by blocking 4-1BB/4-1BB ligand pathway. J Med Dent Sci 2008; 55:207-213.
47. Vinay DS, Cha K, Kwon BS. Dual immunoregulatory pathways of 4-1BB signaling. J Mol Med 2006; 84:726-736.
48. Donners MM, Beckers L, Lievens D, et al. The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling. Blood 2008; 111:4596-4604.
49. Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002; 8:247-252.
50. Choi ET, Khan MF, Leidenfrost JE, et al. Beta3-integrin mediates smooth muscle cell accumulation in neointima after carotid ligation in mice. Circulation 2004; 109:1564-1569.
51. Smyth SS, Reis ED, Zhang W, et al. Beta(3)-integrin-deficient mice but not P-selectin-deficient mice develop intimal hyperplasia after vascular injury: correlation with leukocyte recruitment to adherent platelets 1 h after injury. Circulation 2001; 103:2501-2507.
52. Li G, Sanders JM, BevardMH, et al. CD40 ligand promotesMac-1 expression, leukocyte recruitment, and neointima formation after vascular injury. Am J Pathol 2008; 172:1141-1152.
53. Hristov M, Gumbel D, Lutgens E, et al. Soluble CD40 ligand impairs the function of peripheral blood angiogenic outgrowth cells and increases neointimal formation after arterial injury. Circulation 2010; 121:315-324.
54. Ait-Oufella H, Salomon BL, Potteaux S, et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006; 12:178-180. (Pubitemid 43214743)
55. Taleb S, Tedgui A, Mallat Z. Regulatory T-cell immunity and its relevance to atherosclerosis. J Intern Med 2008; 263:489-499.
56. Gotsman I, Gupta R, Lichtman AH. The influence of the regulatory T lymphocytes on atherosclerosis. Arterioscler Thromb Vasc Biol2007; 27:2493-2495.
57. Kuiper J, van Puijvelde GH, van Wanrooij EJ, et al. Immunomodulation of the inflammatory response in atherosclerosis. Curr Opin Lipidol 2007; 18:521-526.
58. Nakazawa G, Finn AV, Virmani R. Vascular pathology of drug-eluting stents. Herz 2007; 32:274-280.
59. Steffel J, Tanner FC. Biological effects of drug-eluting stents in the coronary circulation. Herz 2007; 32:268-273.
60. Suzuki N, Angiolillo DJ, Monteiro C, et al. Variable histological and ultrasonic characteristics of restenosis after drug-eluting stents. Int J Cardiol 2008; 130:444-448.
61. Sardella G, De LL, Di RA, et al. Comparison between sirolimus- and paclitaxeleluting stent in T-cell subsets redistribution. Am J Cardiol 2006; 97:494-498.
62. Tanaka T, Soejima H, Hirai N, et al. Comparison of frequency of interferongamma- positive CD4 T cells before and after percutaneous coronary intervention and the effect of statin therapy in patients with stable angina pectoris. Am J Cardiol 2004; 93:1547-1549.
63. Brunetti ND, Pepe M, Munno I, et al. Th2-dependent cytokine release in patients treated with coronary angioplasty. Coron Artery Dis 2008; 19:133-137.
64. Navarro-Lopez F, Francino A, Serra A, et al. Late T-lymphocyte and monocyte activation in coronary restenosis. Evidence for a persistent inflammatory/ immune mechanism? Rev Esp Cardiol 2003; 56:465-472.